Comparative Pharmacology
Head-to-head clinical analysis: MANNITOL 5 versus OSMITROL 15 IN WATER IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANNITOL 5 versus OSMITROL 15 IN WATER IN PLASTIC CONTAINER.
MANNITOL 5% vs OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and vasculature, thereby reducing intracranial and intraocular pressure. It also increases renal tubular osmotic pressure, inhibiting water reabsorption and promoting diuresis.
Osmotically active agent that increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing cerebral edema and intraocular pressure.
Intravenous infusion of 50-100 g (as a 5% solution) over 2-6 hours, typically 500-1000 mL, for osmotic diuresis; or for reduction of intracranial pressure, 1-2 g/kg IV over 30-60 minutes as a 15-25% solution.
1.5-2 g/kg intravenous infusion over 30-60 minutes every 6-8 hours as needed for reduction of intracranial pressure or cerebral edema.
None Documented
None Documented
Terminal: 0.25–1.5 h (prolonged in renal impairment); clinical context: accumulates in renal failure, monitor serum osmolarity and renal function
Terminal half-life: 0.25–1.5 hours (15–90 minutes) in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Renal: 90% unchanged; biliary/fecal: negligible (<2%)
Renal: >90% unchanged by glomerular filtration; minimal tubular reabsorption or secretion. <10% metabolized in liver (negligible).
Category A/B
Category C
Osmotic Diuretic
Osmotic Diuretic